NEXTBio Capital Management’s KalVista Pharmaceuticals KALV Stock Holding History

NEXTBio Capital Management’s Portfolio KALV Stock Details KALV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-131,796	Closed	-$2.65M	–	24
2026 Q1	$2.65M	Hold	131,796	–	–	1.23%	22
2025 Q4	$2.13M	Buy	+131,796	New	+$1.75M	1.25%	22

Other funds holding KALV

IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

NEXTBio Capital Management's KALV Position: Q2 2026 in Review

NEXTBio Capital Management sold out of KalVista Pharmaceuticals (KALV) in Q2 2026, closing a stake of 131,796 shares — an estimated $2.65M sold.

NEXTBio Capital Management first reported a position in KALV in Q4 2025 and held it in 2 quarters. The position peaked at $2.65M in Q1 2026. 1 fund tracked by Wall St. Rank holds KALV as of Q2 2026.

NEXTBio Capital Management reported no remaining KalVista Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
NEXTBio Capital Management sold 131,796 KalVista Pharmaceuticals shares in Q2 2026, an estimated $2.65M.
NEXTBio Capital Management first reported a position in KalVista Pharmaceuticals in Q4 2025 and held it in 2 quarters.
NEXTBio Capital Management's KalVista Pharmaceuticals position peaked at $2.65M in Q1 2026.
1 fund tracked by Wall St. Rank held KalVista Pharmaceuticals as of Q2 2026.

Based on NEXTBio Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.